4//SEC Filing
Trenschel Robert J. 4
Accession 0001209191-21-029080
CIK 0001357459other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 5:55 PM ET
Size
20.9 KB
Accession
0001209191-21-029080
Insider Transaction Report
Form 4
Trenschel Robert J.
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-04-27+1,298→ 1,298 totalExercise: $41.20Exp: 2029-06-19→ Common Stock (1,298 underlying) - Award
Warrant (right to buy)
2021-04-27+1,223→ 1,223 total(indirect: By Yuma Regional Medical Center)Exercise: $26.85From: 2020-10-15Exp: 2030-10-15→ Common Stock (1,223 underlying) - Award
Warrant (right to buy)
2021-04-27+13,595→ 13,595 total(indirect: By Yuma Regional Medical Center)Exercise: $41.20From: 2019-08-15Exp: 2029-08-15→ Common Stock (13,595 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+4,406→ 4,406 totalExercise: $26.85Exp: 2030-07-10→ Common Stock (4,406 underlying) - Award
Warrant (right to buy)
2021-04-27+40,785→ 40,785 total(indirect: By Yuma Regional Medical Center)Exercise: $41.20From: 2019-03-08Exp: 2029-03-08→ Common Stock (40,785 underlying) - Award
Common Stock
2021-04-27+304,479→ 304,479 total(indirect: By Yuma Regional Medical Center) - Award
Stock Option (Right to Buy)
2021-04-27+10,182→ 10,182 totalExercise: $41.20Exp: 2029-04-25→ Common Stock (10,182 underlying)
Footnotes (11)
- [F1]Received in exchange for 11,198,208 shares of common stock of Leading BioSciences, Inc. ("LBS"), pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.
- [F10]Received in the Merger in exchange for a warrant to purchase 500,000 shares of LBS common stock for $1.12 per share.
- [F11]Received in the Merger in exchange for a warrant to purchase 45,000 shares of LBS common stock for $0.73 per share.
- [F2]The Reporting Person is the President and Chief Executive Officer of Yuma Regional Medical Center and shares voting and investment power over the securities held by Yuma Regional Medical Center.
- [F3]The stock option vested according to the following schedule: 25% of the shares underlying the option vested on the grant date and the remaining 75% vested in three equal quarterly installments thereafter beginning on June 30, 2019.
- [F4]Received in the Merger in exchange for a stock option to acquire 374,500 shares of LBS common stock for $1.12 per share.
- [F5]The stock option is fully vested.
- [F6]Received in the Merger in exchange for a stock option to acquire 47,758 shares of LBS common stock for $1.12 per share.
- [F7]The stock option vests according to the following schedule: 25% of the shares underlying the option vests on the grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020.
- [F8]Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.
- [F9]Received in the Merger in exchange for a warrant to purchase 1,500,000 shares of LBS common stock for $1.12 per share.
Documents
Issuer
PALISADE BIO, INC.
CIK 0001357459
Entity typeother
Related Parties
1- filerCIK 0001849917
Filing Metadata
- Form type
- 4
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 5:55 PM ET
- Size
- 20.9 KB